Prolonged circulation half-life of interferon γ activity by gene delivery of interferon γ-serum albumin fusion protein in mice

Journal of Pharmaceutical Sciences

Volumn 100, Issue 6, 2011, Pages 2350-2357

  Miyakawa, Noriko ^a   Nishikawa, Makiya ^a   Takahashi, Yuki ^a   Ando, Mitsuru ^a   Misaka, Masayuki ^a   Watanabe, Yoshihiko ^a   Takakura, Yoshinobu ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Albumin; Clearance; Dimerization; Fusion protein; Gene delivery; Hydrodynamic injection; Moment analysis; Pharmacokinetics; Plasmid DNA

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON MOUSE SERUM ALBUMIN FUSION PROTEIN; HYBRID PROTEIN; PLASMID DNA; SERUM ALBUMIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIMERIZATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; GENE TARGETING; LUNG METASTASIS; MALE; MOUSE; NONHUMAN;

EID: 79954626753     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22473     Document Type: Article

References (30)

1. Miller CH, Maher SG, Young HA. 2009. Clinical use of interferon-γ. Ann N Y Acad Sci 1182:69-79.
2. Ferenci P, Brunner H, Nachbaur K, Datz C, Gschwantler M, Hofer H, Stauber R, Hackl F, Jessner W, Rosenbeiger M, Steindl PM, Hegenbarth K, Gangl A, Vogel W. 2001. Combination of interferon induction therapy and ribavirin in chronic hepatitis C. Hepatology 34:1006-1011.
3. Gonias SL, Pizzo SV, Hoffman M. 1988. Clearance and distribution of recombinant murine γ-interferon in mice. Cancer Res 48:2021-2024.
4. Younes HM, Amsden BG. 2002. Interferon-γ therapy: Evaluation of routes of administration and delivery systems. J Pharm Sci 91:2-17.
5. Hamidi M, Zarrin A, Foroozesh M. 2007. Novel delivery system for interferons. Crit Rev Biotechnol 27:111-127.
6. Fujioka K, Takada Y, Sato S, Miyata T. 1995. Novel delivery system for proteins using collagen as a carrier material: The minipellet. J Control Release 33:307-315.
7. Fujioka K, Takada Y, Sato S, Miyata T. 1995. Long-acting delivery system of interferon: IFN minipellet. J Control Release 33:317-323.
8. Harris JM, Chess RB. 2003. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2:214-21.
9. Foster GR. 2004. Pegylated interferons: Chemical and clinical differences. Aliment Pharmacol Ther 20:825-830.
10. Kobayashi N, Kuramoto T, Chen S, Watanabe Y, Takakura Y. 2002. Therapeutic effect of intravenous interferon gene delivery with naked plasmid dna in murine metastasis model. Mol Ther 6:737-744.
11. Kawano H, Nishikawa M, Mitsui M, Takahashi Y, Kako K, Yamaoka K, Watanabe Y, Takakura Y. 2007. Improved anti-cancer effect of interferon gene transfer by sustained expression using CpG-reduced plasmid DNA. Int J Cancer 121:401-406.
12. Hattori K, Nishikawa M, Watcharanurak K, Ikoma A, Kabashima K, Toyota H, Takahashi Y, Takahashi R, Watanabe Y, Takakura Y. 2010. Sustained exogenous expression of therapeutic levels of IFN-gamma ameliorates atopic dermatitis in NC/Nga mice via Th1 polarization. J Immunol 184:2729-2735.
13. Peter T. 1996. All about albumin: Biochemistry, genetics, and medical applications. Academic Press, San Diego.
14. Nomura T, Yasuda K, Yamada T, Okamoto S, Mahato RI, Watanabe Y, Takakura Y, Hashida M. 1995. Gene expression and antitumor effects following direct interferons (IFN)-γ gene transfer with naked plasmid DNA and DC-chol liposome complexes in mice. Gene Ther 6:121-129.
15. Sheffield WP, Mamdani A, Hortelano G, Gataiance S, Smith LE, Begbie ME, Leyva RA, Liaw PS, Ofosu FA. 2004. Effects of genetic fusion of factor IX to albumin on in vivo clearance in mice and rabbits. Br J Haematol 126:565-573.
16. Zhao HL, Yao XQ, Xue C, Wang Y, Xiong XH, Liu ZM. 2008. Increasing the homogeneity, stability and activity of human serum albumin and interferon-α2b fusion protein by linker engineering. Protein Expr Purif 61:73-77.
17. Wriggers W, Chakravarty S, Junnings PA. 2005. Control of protein functional dynamics by peptide linkers. Biopolymers 80:736-746.
18. Takahashi Y, Kaneda H, Takasuka N, Hattori K, Nishikawa M, Takakura Y. 2008. Enhancement of antiproliferative activity of interferons by RNA interference-mediated silencing of SOCS gene expression in tumor cells. Cancer Sci 99:1650-1655.
19. Kobayashi N, Nishikawa M, Takakura Y. 2005. The hydrodynamics-based procedure for controlling the pharmacokinetics of gene medicines at whole body, organ and cellular levels. Adv Drug Deliv Rev 57:713-731.
20. Yamaoka K, Nakagawa T, Uno T. 1978. Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm 6:547-548.
21. dolfo S. 1985. Natural murine interferon-γ. J Biol Chem 260:9936-9940.
22. Schroder K, Hertzog PJ, Ravasi T, Hume DA. 2004. Interferon-γ: An overview of signals, mechanisms and functions. J Leukoc Biol 75:163-189.
23. Farrar MA, Schreiber RD. 1993. The molecular cell biology of interferon-γ and its receptor. Annu Rev Immunol 11:571-611.
24. Ealick SE, Cook WJ, Kumar SV, Carson M, Nagabhushan TL, Trotta PP, Bugg CE. 1991. Three-dimensional structure of recombinant human IFN-γ. Science 252:698-702.
25. Brain VG, Kaita KD, Yoshida EM, Swain MG, Heathcote EJ, Neumann AU, Fiscella M, Yu R, Osborn BL, Cronin PW, Freimuth WW, McHutchison JG, Subramanian GM. 2006. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J Hepatol 44:671-678.
26. Bocci V, Pacini A, Pessina GP, Paulesu L, Muscettola M, Lunghetti G. 1985. Catabolic sites of human interferon-γ. J Gen Virol 66:887-891.
27. Wu J, Xiao X, Jia H, Chen J, Zhu Y, Zhao P, Lin H, Huang W. 2009. Dynamic distribution and expression in vivo of the human interferon gamma gene delivered by adenoviral vector. BMC Cancer 9:55.
28. Subramanian GM, Fiscella M, Smith AL, Zeuzem S, McHutchison JG. 2007. Albinterferon α-2b: A genetic fusion protein for the treatment of chronic hepatitis C. Nat Biotechnol 25:1411-1419.
29. Krause CD, Lunn CA, Izotova LS, Mirochnitchenko O, Kotenko SV, Lundell DJ, Narula SK, Pestka S. 2000. Signaling by covalent heterodimers of interferon-γ. Evidence for one-sided signaling in the active tetrameric receptor complex. J Biol Chem 275:22995-23004.
30. Randal M, Kossiakoff AA. 2001. The structure and activity of a monomeric interferon-γ:α-chain receptor signaling complex. Structure 9:155-163.